[go: up one dir, main page]

JO3353B1 - شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي - Google Patents

شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Info

Publication number
JO3353B1
JO3353B1 JOP/2013/0101A JOP20130101A JO3353B1 JO 3353 B1 JO3353 B1 JO 3353B1 JO P20130101 A JOP20130101 A JO P20130101A JO 3353 B1 JO3353 B1 JO 3353B1
Authority
JO
Jordan
Prior art keywords
low
anamolerin
chloride
organic solvent
molar ratio
Prior art date
Application number
JOP/2013/0101A
Other languages
English (en)
Inventor
De Groot Eleanor
Manini Peter
Yanagimachi Takehiko
Garcia Rubio Silvina
Pines Seemon
Kuwabe Shin-Itsu
Yoshiyama Hideyuki
Original Assignee
Ono Pharmaceutical Co
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3353(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ono Pharmaceutical Co, Helsinn Healthcare Sa filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of JO3353B1 publication Critical patent/JO3353B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

يرتبط الاختراع الحالي بأشكال جسيمية من أحادي هيدروكلوريد الأناموريلين أو المركب الذي يحتوي على أحادي هيدروكلوريد الأناموريلين ذات محتوى الكلوريد المضبوط، الذي يفضل عزله في حالة عدم تبلور و/أو حالة جسيمية دقيقية، كما ويرتبط بعمليات صنع أشكال جسيمية ومركبات صيدلانية تحتوي على أشكال جسيمية.
JOP/2013/0101A 2012-04-20 2013-04-15 شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي JO3353B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20

Publications (1)

Publication Number Publication Date
JO3353B1 true JO3353B1 (ar) 2019-03-13

Family

ID=48225135

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0101A JO3353B1 (ar) 2012-04-20 2013-04-15 شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Country Status (47)

Country Link
US (8) US20140018391A1 (ar)
EP (3) EP2838892B1 (ar)
JP (3) JP6109925B2 (ar)
KR (2) KR101972998B1 (ar)
CN (3) CN110041304A (ar)
AP (1) AP2014008013A0 (ar)
AR (1) AR090725A1 (ar)
AU (1) AU2013249197B2 (ar)
BR (1) BR112014025972A8 (ar)
CA (2) CA2869893C (ar)
CL (1) CL2014002817A1 (ar)
CO (1) CO7131356A2 (ar)
CR (1) CR20140530A (ar)
CY (1) CY1120276T1 (ar)
DK (2) DK3517532T3 (ar)
DO (1) DOP2014000235A (ar)
EA (1) EA031581B1 (ar)
EC (1) ECSP14027739A (ar)
ES (2) ES2820354T3 (ar)
GE (1) GEP20186902B (ar)
HK (2) HK1202863A1 (ar)
HR (1) HRP20180316T1 (ar)
HU (2) HUE035697T2 (ar)
IL (1) IL235064B (ar)
JO (1) JO3353B1 (ar)
LT (1) LT2838892T (ar)
MA (1) MA37524B1 (ar)
MD (1) MD4615C1 (ar)
ME (1) ME02966B (ar)
MX (1) MX354793B (ar)
MY (1) MY170068A (ar)
NI (1) NI201400124A (ar)
NO (1) NO2877697T3 (ar)
NZ (1) NZ700833A (ar)
PE (1) PE20150084A1 (ar)
PH (1) PH12014502351B1 (ar)
PL (2) PL3290410T3 (ar)
PT (2) PT2838892T (ar)
RS (1) RS56869B1 (ar)
SG (2) SG10201608488RA (ar)
SI (2) SI3290410T1 (ar)
TN (1) TN2014000421A1 (ar)
TW (2) TWI677494B (ar)
UA (1) UA116207C2 (ar)
UY (1) UY34753A (ar)
WO (1) WO2013158874A1 (ar)
ZA (1) ZA201408508B (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
EP3188599B1 (en) 2014-09-04 2019-10-02 Helsinn Healthcare SA Medical treatments based on anamorelin
PE20180928A1 (es) 2015-07-24 2018-06-08 Newlink Genetics Corp Sales y profarmacos de 1-metil-d-triptofano
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
EP4021419A1 (en) * 2019-08-30 2022-07-06 Helsinn Healthcare SA Methods of manufacturing anamorelin tablets having improved stability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
CN1882526A (zh) * 2003-09-26 2006-12-20 兰贝克赛实验室有限公司 制备伏格列波糖的方法
US7825138B2 (en) 2004-06-29 2010-11-02 Helsinn Therapeutics (U.S.), Inc. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
TWI677494B (zh) 2019-11-21
CN110041304A (zh) 2019-07-23
KR102141323B1 (ko) 2020-08-05
US20160237115A1 (en) 2016-08-18
US9872883B2 (en) 2018-01-23
EA031581B1 (ru) 2019-01-31
MD20140122A2 (ro) 2015-05-31
NO2877697T3 (ar) 2018-10-13
IL235064B (en) 2019-09-26
EP2838892A1 (en) 2015-02-25
KR101972998B1 (ko) 2019-04-29
JP6616853B2 (ja) 2019-12-04
US20190000914A1 (en) 2019-01-03
EP2838892B1 (en) 2017-12-06
ES2658862T3 (es) 2018-03-12
JP2018076375A (ja) 2018-05-17
CR20140530A (es) 2015-03-25
AU2013249197A1 (en) 2014-10-30
JP2015514779A (ja) 2015-05-21
JP6109925B2 (ja) 2017-04-05
US20190231843A1 (en) 2019-08-01
MD4615B1 (ro) 2019-01-31
ZA201408508B (en) 2020-01-29
US9403867B2 (en) 2016-08-02
SG10201608488RA (en) 2016-12-29
DOP2014000235A (es) 2015-01-31
GEP20186902B (en) 2018-10-25
CL2014002817A1 (es) 2015-08-14
RS56869B1 (sr) 2018-04-30
CN103857669B (zh) 2019-06-28
KR20150013115A (ko) 2015-02-04
CO7131356A2 (es) 2014-12-01
KR20190044697A (ko) 2019-04-30
MD4615C1 (ro) 2019-08-31
EP3290410B1 (en) 2020-07-01
PE20150084A1 (es) 2015-01-23
TW201722928A (zh) 2017-07-01
PT2838892T (pt) 2018-02-28
UA116207C2 (uk) 2018-02-26
EP3290410A1 (en) 2018-03-07
AU2013249197B2 (en) 2017-04-06
EA201401151A1 (ru) 2015-06-30
US20160229889A1 (en) 2016-08-11
US10300105B2 (en) 2019-05-28
IL235064A0 (en) 2014-12-31
UY34753A (es) 2013-11-29
BR112014025972A2 (pt) 2017-06-27
JP2017101082A (ja) 2017-06-08
MA37524B1 (fr) 2017-04-28
US9956261B2 (en) 2018-05-01
US10576122B2 (en) 2020-03-03
JP6284665B2 (ja) 2018-02-28
CN103857669A (zh) 2014-06-11
MX354793B (es) 2018-03-21
CY1120276T1 (el) 2019-07-10
US20140018391A1 (en) 2014-01-16
SI3290410T1 (sl) 2020-11-30
ES2820354T3 (es) 2021-04-20
EP3517532A1 (en) 2019-07-31
ME02966B (me) 2018-07-20
US10905737B2 (en) 2021-02-02
PL2838892T3 (pl) 2018-05-30
US20150072934A1 (en) 2015-03-12
AP2014008013A0 (en) 2014-10-31
PH12014502351A1 (en) 2015-01-12
NZ700833A (en) 2016-01-29
US20160235804A1 (en) 2016-08-18
BR112014025972A8 (pt) 2021-06-22
TW201348224A (zh) 2013-12-01
DK2838892T3 (en) 2018-03-12
US20200276259A1 (en) 2020-09-03
SI2838892T1 (en) 2018-05-31
TWI589572B (zh) 2017-07-01
MY170068A (en) 2019-07-03
MX2014012178A (es) 2015-08-05
US9981002B2 (en) 2018-05-29
CA2869893A1 (en) 2013-10-24
EP3517532B1 (en) 2021-10-13
CA3031652A1 (en) 2013-10-24
PH12014502351B1 (en) 2015-01-12
WO2013158874A1 (en) 2013-10-24
TN2014000421A1 (en) 2016-03-30
CA2869893C (en) 2019-03-05
SG11201406478XA (en) 2014-11-27
ECSP14027739A (es) 2015-12-31
LT2838892T (lt) 2018-03-12
DK3517532T3 (da) 2022-01-03
NI201400124A (es) 2015-09-21
HK1248694A1 (zh) 2018-10-19
CA3031652C (en) 2020-10-27
AR090725A1 (es) 2014-12-03
HUE050865T2 (hu) 2021-01-28
HUE035697T2 (en) 2018-05-28
HK1202863A1 (en) 2015-10-09
PT3517532T (pt) 2021-11-08
PL3290410T3 (pl) 2021-01-11
CN110041398A (zh) 2019-07-23
HRP20180316T1 (hr) 2018-04-06
MA37524A1 (fr) 2016-06-30

Similar Documents

Publication Publication Date Title
JOP20180102A1 (ar) مركب صيدلاني
WO2012058211A3 (en) Quinazoline derivatives, compositions, and uses related thereto
MY172926A (en) Tetrahydropyrazolopyrimidine compounds
MY173521A (en) Trpv4 antagonists
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
HK1198174A1 (en) Azeotrope-like compositions of e-1-chloro-2,3,3,3-tetrafluoropropene and uses thereof e-1--2333-
SG11201601363YA (en) Process for purifying an acid composition comprising 2-formyl-furan-5-carboxylic acid and 2,5-furandicarboxylic acid
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
PL3077453T3 (pl) Kompozycja plastyfikatora zawierająca pochodne tetrahydrofuranu i estry kwasu 1,2-cykloheksanodikarboksylowego
WO2014076712A3 (en) Lurasidone hydrochloride solid dispersion
EP3082823A4 (en) Iminothiadiazepane dioxide compounds as bace inhibitors, compositions, and their use
WO2013164839A3 (en) Amorphous form of apixaban, process of preparation and compositions thereof
MX2016008369A (es) Composicion farmaceutica que incluye palonosetron.
WO2015092810A3 (en) Amorphous form of idelalisib
JO3353B1 (ar) شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
TR201009167A2 (tr) Sefalosporin içeren farmasötik granüller.
WO2013190274A3 (en) Biodegradable compositions
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
IL233682A0 (en) Modified phenylazole derivatives, preparations containing them and their uses
MX358721B (es) Derivados de indeno que tienen afinidad por el receptor sigma, su preparación y su uso como medicamentos.
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
WO2011091410A8 (en) Trpv4 antagonists
WO2014115169A3 (en) Crizotinib solid dispersion
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
MX357796B (es) Composicion fungicida.